Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.

Gailhardou S, Skipetrova A, Dayan GH, Jezorwski J, Saville M, Van der Vliet D, Wartel TA.

PLoS Negl Trop Dis. 2016 Jul 14;10(7):e0004821. doi: 10.1371/journal.pntd.0004821. eCollection 2016 Jul.

2.

Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.

Dayan GH, Mohamed N, Scully IL, Cooper D, Begier E, Eiden J, Jansen KU, Gurtman A, Anderson AS.

Expert Rev Vaccines. 2016 Nov;15(11):1373-1392. Epub 2016 May 9. Review.

PMID:
27118628
3.

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.

Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J.

Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.

4.

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.

Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP.

Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048. Review.

5.

Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.

Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, Dietze R.

Am J Trop Med Hyg. 2013 Dec;89(6):1058-1065. doi: 10.4269/ajtmh.13-0304. Epub 2013 Nov 4.

6.

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

Villar LÁ, Rivera-Medina DM, Arredondo-García JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH.

Pediatr Infect Dis J. 2013 Oct;32(10):1102-9. doi: 10.1097/INF.0b013e31829b8022.

PMID:
24067553
7.

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.

Dayan GH, Thakur M, Boaz M, Johnson C.

Vaccine. 2013 Oct 17;31(44):5047-54. doi: 10.1016/j.vaccine.2013.08.088. Epub 2013 Sep 7.

PMID:
24021313
8.

The history of dengue outbreaks in the Americas.

Brathwaite Dick O, San Martín JL, Montoya RH, del Diego J, Zambrano B, Dayan GH.

Am J Trop Med Hyg. 2012 Oct;87(4):584-93. doi: 10.4269/ajtmh.2012.11-0770.

9.

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.

Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G.

Vaccine. 2012 Oct 19;30(47):6656-64. doi: 10.1016/j.vaccine.2012.08.063. Epub 2012 Sep 7.

PMID:
22959989
10.

Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity.

Cortese MM, Barskey AE, Tegtmeier GE, Zhang C, Ngo L, Kyaw MH, Baughman AL, Menitove JE, Hickman CJ, Bellini WJ, Dayan GH, Hansen GR, Rubin S.

J Infect Dis. 2011 Nov;204(9):1413-22. doi: 10.1093/infdis/jir526. Epub 2011 Sep 20.

PMID:
21933874
11.

Economic impact of dengue illness in the Americas.

Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH.

Am J Trop Med Hyg. 2011 Feb;84(2):200-7. doi: 10.4269/ajtmh.2011.10-0503.

12.

Seroprevalence of antibody to mumps virus in the US population, 1999-2004.

Kutty PK, Kruszon-Moran DM, Dayan GH, Alexander JP, Williams NJ, Garcia PE, Hickman CJ, McQuillan GM, Bellini WJ.

J Infect Dis. 2010 Sep 1;202(5):667-74. doi: 10.1086/655394.

PMID:
20662720
13.

Guidance for isolation precautions for mumps in the United States: a review of the scientific basis for policy change.

Kutty PK, Kyaw MH, Dayan GH, Brady MT, Bocchini JA, Reef SE, Bellini WJ, Seward JF.

Clin Infect Dis. 2010 Jun 15;50(12):1619-28. doi: 10.1086/652770. Review.

PMID:
20455692
14.

The epidemiology of dengue in the americas over the last three decades: a worrisome reality.

San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckenooghe A, Dayan GH, Guzmán MG.

Am J Trop Med Hyg. 2010 Jan;82(1):128-35. doi: 10.4269/ajtmh.2010.09-0346.

15.

Risk factors for mumps at a university with a large mumps outbreak.

Huang AS, Cortese MM, Curns AT, Bitsko RH, Jordan HT, Soud F, Villalon-Gomez J, Denning PM, Ens KA, Hanson GR, Dayan GH.

Public Health Rep. 2009 May-Jun;124(3):419-26.

16.

Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?

Dayan GH, Rubin S.

Clin Infect Dis. 2008 Dec 1;47(11):1458-67. doi: 10.1086/591196.

PMID:
18959494
17.

Mumps vaccine performance among university students during a mumps outbreak.

Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, Dayan GH.

Clin Infect Dis. 2008 Apr 15;46(8):1172-80. doi: 10.1086/529141.

PMID:
18444852
18.

Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.

Date AA, Kyaw MH, Rue AM, Klahn J, Obrecht L, Krohn T, Rowland J, Rubin S, Safranek TJ, Bellini WJ, Dayan GH.

J Infect Dis. 2008 Jun 15;197(12):1662-8. doi: 10.1086/588197.

PMID:
18419346
19.

Recent resurgence of mumps in the United States.

Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O'Keefe AL, Clayton J, Kightlinger LK, Dietle EG, Berg J, Kenyon CL, Goldstein ST, Stokley SK, Redd SB, Rota PA, Rota J, Bi D, Roush SW, Bridges CB, Santibanez TA, Parashar U, Bellini WJ, Seward JF.

N Engl J Med. 2008 Apr 10;358(15):1580-9. doi: 10.1056/NEJMoa0706589.

20.

Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage.

Bitsko RH, Cortese MM, Dayan GH, Rota PA, Lowe L, Iversen SC, Bellini WJ.

J Clin Microbiol. 2008 Mar;46(3):1101-3. doi: 10.1128/JCM.01803-07. Epub 2008 Jan 9.

Supplemental Content

Loading ...
Support Center